Navigation Links
BMP Sunstone Reports Second Quarter 2008 Financial Results
Date:8/11/2008

he population needs treatment for the disease.

On July 7, 2008, BMP Sunstone announced that it received the New Business License for BMP Sunstone's establishment of an Enterprise with Foreign Investment in the People's Republic of China, from the Shanghai Administration for Industry and Commerce (SHAIC). With receipt of this license, BMP Sunstone completed the acquisition of 63.3 percent of Shanghai Rongheng Pharmaceutical Co., Ltd. (''Rongheng''). Through this acquisition, BMP Sunstone has gained direct coverage of 80 percent of the top-tier hospitals and 40 percent of the retail pharmacies in Shanghai.

On July 18, 2008, BMP Sunstone signed a non-binding letter of intent to acquire 75 percent of Zhangjiakou Shengda Pharmaceutical Co., Ltd (''Shengda'') for up to RMB 30.0 million (approximately $4.4 million). The Company expects to complete the transaction by the end of the fourth quarter of 2008. Terms of the acquisition are not yet finalized, as completion is subject to a number of conditions, including finalization of due diligence and definitive documentation. The Company intends to use the cash available at Sunstone to fund the acquisition. The letter of intent also includes a six month exclusivity clause.

Financial Outlook

The Company is raising its guidance for 2008 revenues from at least $96.0 million to a range of $110 to $120 million. This increase is attributable to the addition of Rongheng as well stronger than expected organic growth from our existing business. The Company is expecting to have non-GAAP net income of $4.0 million to $5.0 million. Our non-GAAP guidance of net income excludes stock based compensation, amortization related to the acquisition of Sunstone and Wanwei and debt discount amortization and issuance costs related to the $23 million debt issued in November 2007. The Company's financial guidance also excludes any potential or pending acquisitions, new product launches and profit sharing from Alliance BMP Li
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
2. BMP Sunstone Receives Import Drug License (IDL) from SFDA
3. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
4. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
10. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
11. Isis Reports Financial Results and Highlights for Second Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3
... Primary ... SAN DIEGO, May 27 Favrille, Inc. (Nasdaq:,FVRL) ... trial,of Specifid(TM) following Rituxan(R) in patients with follicular B-cell,non-Hodgkin,s ... Analysis of time to progression (TTP), the primary endpoint ...
... May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... research,and development outsourcing company with operations in ... that it has appointed Dr. Peng Wang ... http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Prior to ...
... SAN DIEGO, May 23 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Stockholders on,Friday, May 30, 2008 at 11:00 a.m. PT ... the Annual Meeting, Daniel M.,Bradbury, President and Chief Executive ... The live presentation will be Web cast, and ...
Cached Biology Technology:Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology 2
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... with fossils led to Natural Sciences and Engineering Research Council ... the oldest known reptile that stands on two legs. ... years of research excellence by joining the ranks of the ... will induct him as a fellow during its annual conference, ...
... pinpointed a natural ingredient of human blood that effectively ... from infecting immune cells and multiplying. The virus blocker ... to full-blown AIDS and—because it works in a different ... of another class of drugs in the fight against ...
... the influenza virus that killed 50 million people in 1918, ... to how the virus killed so quickly and efficiently. , ... a team led by University of Wisconsin-Madison virologist Yoshihiro Kawaoka ... influenza strain - unleashes an immune response that destroys the ...
Cached Biology News:Old dinosaur research leads to new honor 2Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3Study uncovers a lethal secret of 1918 influenza virus 2Study uncovers a lethal secret of 1918 influenza virus 3
... The Z-Competent E. coli Transformation Buffer ... of competent E. coli cells for simple ... method completely eliminates the requirement for heat ... transformation can be performed by adding DNA ...
Request Info...
Buffer used for mitocapture assays....
... automated perfusion system. For real-time or ... biophysics, electrochemistry, or general liquid-handling research ... millisecond accuracy Run experiments automatically ... accuracy and flexibility Turnkey perfusion ...
Biology Products: